LISATA THERAPEUTICS INC (LSTA)

US1280583022 - Common Stock

2.75  -0.02 (-0.72%)

Premarket: 2.8 +0.05 (+1.82%)

Full profile views are only available for registered users, you can see which data is available below.

Examples of complete profiles are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional data.

LISATA THERAPEUTICS INC

NASDAQ:LSTA (5/7/2024, 7:08:10 PM)

Premarket: 2.8 +0.05 (+1.82%)

2.75

-0.02 (-0.72%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
Chartmill FA Rating
Valuation
Growth
Profitability
Health
Dividend
Overview
Earnings (Last)
Earnings (Next)
Ins Owners
Inst Owners
Market Cap22.85M
Shares
PEN/A
Fwd PEN/A
Dividend YieldN/A
Analysts
IPO
Stock Screener Links
Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

LSTA Daily chart

Company Profile

Lisata Therapeutics, Inc. develops biopharmaceuticals. The company is headquartered in Basking Ridge, New Jersey and currently employs 27 full-time employees. The firm is engaged in the discovery, development, and commercialization of therapies for the treatment of advanced solid tumors and other diseases. Its lead investigational product candidate, LSTA1, is designed to activate a novel uptake pathway that allows co-administered or tethered anti-cancer drugs to penetrate solid tumors. LSTA1 actuates this active transport system in a tumor-specific manner, resulting in systemically co-administered anti-cancer drugs penetrating and accumulating in the tumor, while normal tissues are not affected. LSTA1 also has the potential to modify the tumor microenvironment (TME). LSTA1 also has the potential to modify the tumor microenvironment. The company is exploring the potential of LSTA1 to enable a variety of treatment modalities to treat a range of solid tumors. In addition, it has clinical development programs based on its autologous CD34+ cell therapy technology platform.

Company Info

LISATA THERAPEUTICS INC

110 Allen Road, Second Floor

Basking Ridge NEW JERSEY

P: 19082292590

Employees: 27

Website: https://www.lisata.com/

LSTA News

News Image14 hours ago - Lisata Therapeutics, Inc.Lisata Therapeutics to Participate in Upcoming May 2024 Industry and Investor Events
News Image7 days ago - Lisata Therapeutics, Inc.Lisata Therapeutics to Report First Quarter 2024 Financial Results and Provide a Business Update on Thursday, May 9, 2024
News Image7 days ago - Lisata Therapeutics, Inc.Lisata Therapeutics to Report First Quarter 2024 Financial Results and Provide a Business Update on Thursday, May 9, 2024

BASKING RIDGE, N.J., May 02, 2024 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage...

News Image16 days ago - Lisata Therapeutics, Inc.Lisata Therapeutics and Qilu Pharmaceutical Announce First Patient Treated in Qilu’s Phase 2 Trial in China of LSTA1 in Patients with Metastatic Pancreatic Ductal Adenocarcinoma

Results of Phase 1b/2 in China reinforce global clinical development rationale and plans for LSTA1

News Image16 days ago - Lisata Therapeutics, Inc.Lisata Therapeutics and Qilu Pharmaceutical Announce First Patient Treated in Qilu’s Phase 2 Trial in China of LSTA1 in Patients with Metastatic Pancreatic Ductal Adenocarcinoma

Results of Phase 1b/2 in China reinforce global clinical development rationale and plans for LSTA1...

News Imagea month ago - Lisata Therapeutics, Inc.Lisata Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to LSTA1 for the Treatment of Osteosarcoma

LSTA Twits

Here you can normally see the latest stock twits on LSTA, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example